key: cord-0848309-bbw28ud5 authors: Joerger, M.; Metaxas, Y.; Zaman, K.; Michielin, O. A.; Mach, N.; Betticher, D.; Schmitt, A. M.; Cantoni, N.; Caspar, C. B.; Stettler, S.; Malval, R.; Pless, M.; Britschgi, C.; Renner, C.; Koeberle, D.; Schulz, J.; Kopp, C.; Hayoz, S.; Stathis, A.; von Moos, R. title: 1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20 date: 2021-09-30 journal: Annals of Oncology DOI: 10.1016/j.annonc.2021.08.1563 sha: d921733245835f811a1ccbfc25f240342b5ce274 doc_id: 848309 cord_uid: bbw28ud5 nan Oncologic Center, HM CIOCC -Centro Integral Oncológico Clara Campal, Barcelona, Spain; 16 Medical Oncology, Hospital Universitario Puerta de Hierro, Madrid, Spain Background: SARS-CoV-2 infection can induce a host hyperinflammatory response induced by a cytokine storm, that is the main cause of mortality. Myelosuppression is associated with higher risk of infections and mortality. Few reports have addressed about the management of patients with neutropenia and COVID-19. Herein, we present a retrospective study during COVID-19 outbreak in neutropenic cancer patients with COVID-19 comparing the outcome and survival between G-CSF treated vs G-CSF non-treated group. Methods: Retrospective data were collected from clinical reports. Inclusion criteria were cancer with neutropenia (<1500 cells/mm3) and concomitant COVID-19 infection. Comorbidities, tumor, stage, treatment, neutropenia severity, G-CSF, COVID-19 parameters and mortality were analyzed. Exploratory analysis of both cohorts (G-CSF treated and G-CSF non treated) and a multivariable logistic regression was done to predict respiratory failure and death. Results: Among 943 patients with cancer and COVID-19 from14 hospitals in Spain, 8% had neutropenia. Two cohorts according to G-CSF treatment were identified: 40 patients received G-CSF vs 43 G-CSF non-treated. Lung (26%) was the main location and most had advanced disease (67%). No differences according to baseline characteristics were found, except for the cancer treatment and the center s protocols for neutropenia management (p¼0,001). 63% of patients died because respiratory failure. Neumonia was presented in 76% of patients. Patients treated with G-CSF had a higher rate of respiratory failure vs non-treated (p¼0.001) and required oxygen support (p¼0.002). In G-CSF treated cohort, we found that the days with G-CSF showed a significant trend toward worse outcome and higher mortality. A logistic regression model was developed to predict respiratory failure as a function of the days of G-CSF treatment. After adjusting several relevant covariates, a significant effect was obtained for the days of G-CSF treatment (OR ¼ 1.4, 95% CI [1.03, 1.92], p-value ¼ 0.01). Conclusions: Our findings suggest that G-CSF treatment could be disadvantageous in cancer patients with COVID-19, with a probable worse outcome. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Conclusions: COVID-19 positivity rates were not increased for individuals with active cancer diagnoses in the UC Cancer Consortium. A lower positivity rate amongst cancer patients may be due to demographic, behavioral, occupational or environmental factors, as well as greater asymptomatic testing of cancer patients at some UC sites. Interactions with local prevalence and patient and cancer characteristics will be presented. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. https://doi.org/10.1016/j.annonc.2021.08.1564 Funding: Roche/Genentech; Financial Interests, Personal, Other, travel expenses: MSD Oncology; Financial Interests, Personal, Other, travel expenses: Pierre Fabre; Financial Interests, Personal, Other, travel expenses: Roche Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Glaxo-Smith-Kline; Financial Interests, Personal, Advisory Board: Pierre-Fabre; Financial Interests Personal, Funding: MSD; Financial Interests, Personal, Funding: Amgen; Financial Interests Funding: Roche; Financial Interests, Institutional, Funding: Novartis; Financial Interests, Institutional, Funding: MSD; Financial Interests, Institutional, Funding: Bristol-Meyers Squibb; Financial Interests, Institutional, Funding: Abbvie; Financial Interests, Institutional, Funding: Pfizer; Financial Interests, Institutional, Funding: Merck; Financial Interests, Institutional, Funding: Amgen; Financial Interests, Institutional, Funding: Philogen; Financial Interests, Personal, Stocks/Shares: MaxiVAX. N. Cantoni: Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: Alexion; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Bristol-Meyers Squibb; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: Gilead; Financial Interests, Personal, Advisory Board: Incyte Advisory Board: OrPha Swiss; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests Financial Interests, Personal, Advisory Board: Shire Funding: AstraZeneca; Financial Interests, Personal, Funding: CLS Behring; Financial Interests, Personal, Funding: Novartis; Financial Interests, Personal, Funding: Pierre-Fabre; Financial Interests, Personal, Funding: Shire (Baxter Oncology). M. Pless: Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bristol-Meyers Squibb; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Other, travel grants: AstraZeneca; Financial Interests, Personal, Other, travel grants: Bristol-Meyers Squibb; Financial Interests, Personal, Other, travel grants: Boehringer Ingelheim. C. Britschgi: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal Financial Interests, Personal, Other, travel grants: AbbVie. R. von Moos: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Pierre-Fabre; Financial Interests Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Vifor. All other authors have declared no conflicts of interest 1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium Bakar Computational Health Sciences Institute, UCSF Helen Diller Family Comprehensive Cancer Center Background: The impact of active cancer on susceptibility to coronavirus disease 2019 (COVID-19) remains controversial. This study leverages the infrastructure across the University of California (UC) Cancer Consortium This data set collects COVID-19 test results from the 5 academic medical centers in the UC Health System and their NCI-designated Comprehensive Cancer Centers. COVID-19 test results were identified by Logical Observation Identifiers Names and Codes (LOINC)